Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award

Published on by China Scientist

Prof. Dr. Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award 

Zengchun Hu is a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, specializing in the surgical and comprehensive treatment of gliomas, malignant brain tumors, and cerebrovascular diseases. A doctoral graduate in neurosurgery from Dalian Medical University, he further trained at Beijing Tian Tan Hospital to refine advanced surgical skills. He has contributed extensively to national research projects, published in leading SCI journals, and authored a neurosurgical textbook. His research explores lipid and sugar metabolism, ferroptosis, and targeted therapies in glioma and lung cancer, aiming to develop innovative treatment strategies that improve patient outcomes.

Prof. Dr. Zengchun Hu | The Second Affiliated Hospital of Dalian Medical University | China

Profile

SCOPUS

Education

  • Zengchun Hu earned his doctoral degree in neurosurgery from Dalian Medical University, establishing a strong foundation in surgical techniques and clinical neurology. He further enhanced his expertise through subspecialization training in neurosurgery at Beijing Tian Tan Hospital, where he refined advanced skills in managing complex neurological conditions. His academic journey combined rigorous research engagement with extensive clinical exposure, preparing him for a career at the forefront of neurosurgical innovation.

Experience

  • Currently serving as a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, Zengchun Hu has built a reputation for his precision and dedication in neurosurgical care. He is highly experienced in performing surgeries for gliomas, malignant brain tumors, and cerebrovascular diseases. His surgical proficiency allows him to independently handle a large number of brain tumor operations annually. In addition to his clinical work, he has contributed to multiple national-level research projects and has authored numerous peer-reviewed articles in high-impact scientific journals.

Awards and Recognition

  • Zengchun Hu’s leadership in neurosurgery and his academic contributions have earned him recognition within both clinical and research communities. As the editor-in-chief of a specialized neurosurgical textbook published by Jilin Science and Technology Press, he has contributed to shaping the educational landscape for upcoming neurosurgeons. His appointment as an editorial board member for the Translational Medicine Electronic Journal and his role as a young editor further reflect his standing as a respected thought leader in his field.

Skills and Expertise

  • Zengchun Hu possesses exceptional skills in brain tumor surgery, cerebrovascular disease management, and advanced neurosurgical techniques. His expertise extends to integrating traditional and modern medical approaches in neurosurgical care. He is adept at leading multidisciplinary teams, mentoring doctoral candidates, and translating cutting-edge research findings into practical therapeutic strategies. His academic and clinical synergy ensures comprehensive patient care while advancing neurosurgical science.

Research Focus 

  • Zengchun Hu’s research is centered on the surgical and comprehensive treatment of gliomas and other malignant tumors. He investigates the mechanisms of lipid and sugar metabolism as well as ferroptosis in the development of gliomas and lung cancer. His studies have highlighted the therapeutic potential of targeting SVIP in glioblastoma progression and have revealed the anti-cancer effects of CPP through Nrf2 degradation and ferroptosis sensitization in non-small cell lung cancer. His work aims to develop novel therapeutic strategies that combine surgery with targeted molecular treatments to improve survival and quality of life for cancer patients.

Publications

  • Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2
    Authors: Jinhao Wang, Yue Zhu, Jialiang Song, Fengping Yang, Peng Wang, Ziyi Zhang, Yuxuan Li, Minghe Dai, Yinuo Wang, Waleed Yousuf, Jiayu Li, Dian Yang, Shaoxuan Cheng, Shuyan Liu, Zhaoxia Dai, Xun Qiu, Yingqiu Zhang, Zengchun Hu
    Journal: Cancer Cell International

  • Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells
    Authors: Di Wu, Yang Zhang, Luna Zhang, Wanying Xia, Bingkun Cai, Feihong Dong, Ke Wu, Lichun Cheng, Mingkun Shao, Hui Ma, Zengchun Hu, Huiyi Lu
    Journal: OncoTargets and Therapy

  • SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN
    Authors: Zixuan Wang, Xiaolong Qiao, Yinan Chen, Nan Peng, Chaoshi Niu, Yang Wang, Cong Li, Zengchun Hu, Caihua Zhang, Chuandong Cheng
    Journal: Cell Death Discovery

  • Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth
    Authors: Yu Long, Zengchun Hu, Dian Yang, Fuqiang Wang, Chen’ge Zhao, Yang Zhang, Yingqiu Zhang, Hui Ma, Huiyi Lv
    Journal: Open Life Sciences

  • Tanshinone IIA Microemulsion Protects against Cerebral Ischemia Reperfusion Injury via Regulating H3K18ac and H4K8ac In Vivo and In Vitro
    Authors: Hui Ma, Zeng-Chun Hu, Yu Long, Li-Chun Cheng, Chen-Yang Zhao, Ming-Kun Shao
    Journal: American Journal of Chinese Medicine

Conclusion

  • Through his combined roles as a surgeon, educator, and researcher, Zengchun Hu has established himself as a prominent figure in neurosurgery. His work reflects a dedication to improving surgical outcomes, advancing research in cancer treatment, and mentoring the next generation of neurosurgical specialists. By aligning clinical practice with scientific discovery, he continues to make a significant impact in both patient care and medical research.

Guangzhong Guo | Glioma | Best Researcher Award

Published on by China Scientist

Dr. Guangzhong Guo | Glioma | Best Researcher Award

Guangzhong Guo is a resident physician at Zhoukou Central Hospital and a master’s graduate of Zhengzhou University. Specializing in glioma and circulating tumor DNA (ctDNA), he has published four SCI papers and completed two research projects. His work focuses on using ctDNA for dynamic monitoring of glioma recurrence and progression. With expertise in oncological diagnostics and molecular pathology, he integrates research into clinical practice to enhance patient care. He has also contributed to consultancy and industry projects, further advancing neuro-oncology.

Dr. Guangzhong Guo | Zhengzhou University | China

Profile

ORCID ID

🎓Education

  • Guangzhong Guo obtained his master’s degree from Zhengzhou University, where he focused on medical research related to glioma and circulating tumor DNA (ctDNA). His academic journey has been marked by a strong commitment to advancing cancer diagnostics and treatment strategies.

👨‍🏫Experience

  • Currently serving as a resident physician at Zhoukou Central Hospital, Guangzhong Guo applies his medical expertise in clinical settings, contributing to patient care and oncology research. His role involves diagnosing and treating glioma cases while integrating research findings into practical applications for improved patient outcomes.

🏆Awards and Recognitions

  • With a strong academic and clinical background, Guangzhong Guo has been actively involved in oncology research and has contributed to consultancy and industry projects. His dedication to advancing glioma treatment and diagnostics has earned him recognition within the medical research community.

đź’ˇSkills and Certifications

  • His core competencies include oncological diagnostics, molecular pathology, and clinical research methodologies. He is adept at analyzing ctDNA for glioma progression monitoring, integrating research insights into patient care, and contributing to innovative treatment approaches.

🔬 Research Focus

  • Guangzhong Guo’s primary research areas include glioma and ctDNA. His work on dynamic ctDNA monitoring offers precise insights into glioma recurrence patterns, enabling better treatment planning and personalized patient management. His commitment to bridging clinical practice with cutting-edge research continues to drive advancements in neuro-oncology.

🌎Conclusion

  • Guangzhong Guo is a highly deserving candidate for the Best Researcher Award due to his groundbreaking contributions to glioma research, commitment to scientific excellence, and impactful clinical applications. His work on ctDNA has the potential to revolutionize glioma diagnosis, recurrence prediction, and treatment monitoring, making him an invaluable asset to the field of neuro-oncology.

đź“–Publications

  • Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma
    Author: Guangzhong Guo et al.
    Journal: Cancer Medicine

  • Dynamics of Tumor In Situ Fluid Circulating Tumor DNA in Recurrent Glioblastomas Forecasts Treatment Efficacy of Immune Checkpoint Blockade Coupled with Low-Dose Bevacizumab
    Author: Guangzhong Guo et al.
    Journal: Journal of Cancer Research and Clinical Oncology

  • Predicting Recurrent Glioblastoma Clinical Outcome to Immune Checkpoint Inhibition and Low-Dose Bevacizumab with Tumor In Situ Fluid Circulating Tumor DNA Analysis
    Author: Guangzhong Guo et al.
    Journal: Cancer Immunology, Immunotherapy

  • Tracking Tumor Evolution During the First-Line Treatment in Brain Glioma via Serial Profiling of Cell-Free Tumor DNA from Tumor In Situ Fluid
    Author: Guangzhong Guo et al.
    Journal: Frontiers in Oncology

  • Molecular and Clonal Evolution In Vivo Reveal a Common Pathway of Distant Relapse Gliomas
    Author: Guangzhong Guo et al.
    Journal: iScience

Xingyao Bu | Glioma | Best Researcher Award

Published on by China Scientist

Prof. Dr. Xingyao Bu | Glioma | Best Researcher Award

Professor Xingyao Bu is the Chief Physician and Director of the Department of Neurosurgery at Juha International Center for Neurosurgery, Zhengzhou University People’s Hospital. A leading expert in precision minimally invasive therapy for gliomas, he specializes in in-vivo gene evolution and personalized treatment strategies. He has led 15 completed and two ongoing research projects, published 22 SCI papers, and holds 15 patents. As an editorial board member of multiple journals and a key figure in neurosurgical associations, his work in ctDNA research and precision medicine has significantly advanced glioma diagnosis, prognosis, and treatment.

Prof. Dr. Xingyao Bu | Zhengzhou University People’s Hospital | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Professor Xingyao Bu holds an M.D. degree and has completed postdoctoral research in neurosurgery. As a graduate supervisor, he has been dedicated to mentoring and training the next generation of medical professionals in the field of neurosurgery.

👨‍🏫Experience

  • Currently serving as the Chief Physician and Director of the Department of Neurosurgery at Juha International Center for Neurosurgery, Zhengzhou University People’s Hospital, Professor Bu is also the Director of the Glioma Subspecialty Division. He specializes in precision minimally invasive targeted therapy for central nervous system tumors, particularly gliomas. His expertise extends to in-vivo genetic evolution studies of gliomas and the development of personalized treatment strategies.

🏆Awards and Recognitions

  • Professor Bu is an esteemed expert enjoying special government allowances and has been recognized as an outstanding young science and technology expert, a young and middle-aged scientific and technological innovation talent, and a cross-century discipline leader. He has also been honored as an advanced individual returning from studying abroad and has received the Outstanding Youth and Outstanding Talent Innovation Fund. His contributions to the field have earned him a position as an expert evaluator for national science and technology awards and a candidate for the National “Hundred-Thousand-Ten Thousand Talents Project.”

đź“ť Editorial and Professional Contributions

  • Professor Bu serves on the editorial boards of over ten prestigious medical journals, including the Journal of Clinical Neurosurgery and the Chinese Journal of Practical Diagnosis and Therapy. He is an active member of several key professional organizations, including the Glioma Committees of the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. Additionally, he holds leadership roles as the Deputy Chairman of the Neurosurgery Branch of the Henan Medical Association and the Neurosurgery and Cerebrovascular Disease Professional Committee of the Henan Medical Science Popularization Association.

đź’ˇSkills and Certifications

  • With extensive experience in neurosurgical precision techniques, Professor Bu has contributed to 15 published and ongoing patents. He has led 15 completed and two ongoing research projects, authored 22 SCI-indexed publications, and collaborated on multiple consultancy and industry projects. His work in minimally invasive surgery and personalized glioma treatment continues to push the boundaries of neurosurgical innovation, significantly impacting patient outcomes.

🔬 Research Focus

  • His research primarily explores gliomas, ctDNA, immunotherapy, precision medicine, gene evolution, minimally invasive surgery, and individualized treatment. His groundbreaking work on circulating tumor DNA (ctDNA) in tumor in-situ fluid (TISF) after glioma surgery has provided real-time, dynamic insights into the genetic evolution of gliomas. This research has significantly advanced the understanding of tumor recurrence, prognosis prediction, and immunotherapy strategies.

🌎Conclusion

  • Given his remarkable achievements in glioma research, high-impact publications, leadership roles, and contributions to precision medicine, Dr. Xingyao Bu is highly suitable for the Best Researcher Award. His pioneering work has transformed the landscape of glioma treatment, making lasting contributions to the field of neurosurgery and oncology. Recognizing his excellence with this award would not only honor his past achievements but also inspire further advancements in brain tumor research.

đź“–Publications

  • Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
    Authors: D. Wang, J. Zhang, C. Bu, C. Ma, X. Bu
    Journal: Journal of Cancer Research and Clinical Oncology, 2024

  • Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
    Authors: G. Guo, Z. Zhang, J. Zhang, T. Li, X. Bu
    Journal: Cancer Immunology Immunotherapy, 2024

  • Molecular and clonal evolution in vivo reveal a common pathway of distant relapse gliomas
    Authors: G. Liu, C. Bu, G. Guo, M. Li, X. Bu
    Journal: iScience, 2023

  • Genomic alterations of oligodendrogliomas at distant recurrence
    Authors: G. Liu, C. Bu, G. Guo, M. Li, X. Bu
    Journal: Cancer Medicine, 2023

  • Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability
    Authors: C. Bu, S. Hu, J. Yu, Z. Yan, X. Bu
    Journal: Clinical and Translational Oncology, 2023